



ALLENEX AB (PUBL)

YEAR-END REPORT 2013

For the fourth quarter October-December

- Net sales for the quarter amounted to SEK 29.4 million (27.4). Sales were impacted by a positive currency effect of SEK 0.3 million compared to the same period last year.
- Operating income (EBIT) for the quarter was SEK 2.2 million (0.6), with currency effects having a positive impact of SEK 0.6 million compared to the same period last year.
- Operating margin for the quarter was 8 percent (2).
- Earnings after tax for the quarter were SEK 0.1 million (0.9).
- Earnings per share for the quarter, basic and diluted, were SEK 0.02 (0.03).

For the January-December period

- Net sales for the year amounted to SEK 111.8 million (112.7). Sales were impacted by a negative currency effect of SEK 1.6 million compared to last year.
- Operating income (EBIT) for the year was SEK 9.6 million (7.9), with currency effects having a negative impact of SEK 1.9 million compared to last year.
- Operating margin for the year was 8 percent (7).
- Earnings after tax for the year were SEK 2.3 million (0.3).
- Earnings per share for the year, basic and diluted, were SEK 0.05 (0.04).

Allenex president and CEO Anders Karlsson's commentary on the fourth quarter 2013:

"Allenex as a whole grew over 7 percent in the fourth quarter compared to the same period last year. Sales in the U.S. performed very well, up 40 percent compared to 2012. In particular, an increase in sales in the SBT segment lies behind the growth we are seeing in North America, where several new centers started clinical testing with SBT Resolver™ in the second half of 2013. We are also positive about the European market, where we successfully met last year's sales figures, despite a challenging business environment. Our geographic expansion of the Olerup SSP® product line continues and we are working actively to secure product registration and new distribution channels in growth markets."

For additional information, please contact:

Anders Karlsson, CEO, tel: +46 (0)70-918 00 10 or email: anders.karlsson@allenex.se


Yvonne Axelsson, CFO, tel: +46 (8) 508 939 72 or email: yvonne.axelsson@allenex.se

GROUP PERFORMANCE

Allenex is a life science company that develops, manufactures, markets and sells products on the global market that facilitate safer transplantation of blood stem cells and organs. Allenex is listed on NASDAQ OMX Stockholm, Small Cap, (ticker: ALNX). There are 55 employees in the Allenex group.

SALES

Net sales for the fourth quarter amounted to SEK 29.4 million (27.4), corresponding to an increase of 7 percent.



Sales in the fourth quarter mainly comprised HLA typing kits based on SSP technology.

Sales in North America increased by 40 percent in local currency (USD) during the fourth quarter compared to the same period last year. In particular, an increase in sales in the SBT segment lies behind the growth in North America in the fourth quarter.

During the first six months of the year, Allenex reported lower sales in Europe than last year. This was due to a significant fall in the number of new donors in Germany because of, among other things, the transplantation scandal that arose in early 2013. Consequently, the number of transplants was down by around 20 percent in one of the company's single largest markets in Europe. The strained financial climate is also deemed to have had a certain role in the fall in sales in Europe. Sales recovered, however, during the third and fourth quarters of 2013. In the fourth quarter, we continued to see the positive sales effect of the four-year public tender contract that Allenex won in autumn 2012 in collaboration with a local distributor in France.

Allenex work to expand geographically to countries outside Europe and North America continues according to plan and during the second quarter Allenex SSP products were approved for sale in Mexico. The local distributor already generated sales in the second half of 2013. In China, Brazil, South Korea, Belarus and Canada, work is ongoing to register the company's products. Furthermore, work to secure strong local sales partners/distributors in these markets is underway.

CUSTOMER GROUPS

Allenex customers largely constitute laboratories active in transplantation diagnostics. Today there are three different technologies on the market for HLA typing (SSP, SSO and SBT), where the most common typing technique globally in terms of volume is SSO. However, most laboratories use SSP typing, either as a primary or complementary technique. The size of the laboratory and its level of automation determines how much of respective technologies are used. Today, the largest laboratories mainly use automated solutions (SBT and SSO) as their primary technology, while smaller laboratories generally prefer SSP typing. Subsequently, the choice of typing technology is a key parameter for customer categorization.

All large Allenex competitors offering automated SSO or SBT solutions (OneLambda, Life Technologies, Abbott Laboratories) also provide SSP products.

Even smaller laboratories are increasingly adopting more automated solutions and Allenex is therefore working to meet market requirements, in part through proprietary product development, and in part through partnerships with other companies. Since mid-2011, Allenex is the exclusive global distributor of the HLA typing products SBT Resolver™ and the related software Assign-SBT™ from the Australian company Conexio Genomics. SBT Resolver™ was introduced by Allenex in the second half of 2011. This strategically important contract gives Allenex greater opportunity to partner with larger, automated laboratories. Since these laboratories increasingly tend to use the same supplier for all HLA typing products, this contract will facilitate increased sales opportunities for Allenex SSP products. SBT Resolver™ has been introduced to a large number of potential customers. Following an introductory demonstration, the laboratory usually conducts an independent comparison to the product currently in use. If the comparison favors Allenex, careful product validation is then carried out prior to fully converting to SBT Resolver™.

The validation process tends to be relatively long, usually taking from 6 to 15 months. To date, 24 laboratories have converted, partially or fully, to SBT Resolver™, (9 in North America and 15 in Europe) and around 20 laboratories are currently validating the product. An additional 20 or so laboratories are currently comparing SBT Resolver™ to their current product.

MARKET DEVELOPMENT

The strategy is to introduce SBT Resolver™ to the largest and most automated HLA laboratories in the U.S. and Europe. A number of these laboratories have very high volumes as they conduct tests for national or regional typing registers. Major register typing laboratories conduct HLA typing tests on more than 5,000 individuals per year and are very careful in their evaluation of new suppliers, which leads to long sales processes. Purchasing patterns are further impacted by the fact that laboratories maintain major invento-

ries of tests, ordering every 3 to 6 months. In the U.S., in particular, larger laboratories where SBT typing is used for clinical typing are also found. These laboratories type between 2,000 to 3,000 tissue samples per year. Allenex has chosen to focus on these major laboratories as they hold high value as reference customers, which is important in this segment. Moreover, the sales potential at these laboratories is significantly higher than at other, smaller laboratories.

Conexio has collaborated with partners and distributors since it started producing reagents on a commercial basis in 1998, followed by software for SBT typing. Since 2009, the current market leader has in-licensed PCR primers from Conexio for its typing kit (to type the HLA-DRB1 gene) as well as the Conexio-developed software program Assign-SBT™ 3.6. This contract expired at the year-end 2013 and the competitor had to find a new partner in terms of software and DRB1 kits.

Since January 1, 2014, Assign SBT™ is solely available through Allenex and Conexio. The software is a key part of analysis and is often what sets the offering apart from those of other SBT suppliers. Changing software is considered by many tissue typing laboratories to be very resource intensive. Consequently, Allenex sees great market potential in being exclusively able to offer Assign-SBT™3.6+ as well as the recently introduced fourth generation of this software, Assign-SBT™4.7+. This is done cost free as a part of our product offering to those customers who choose to work with SBT Resolver™. These software programs are upgraded versions of those previously offered by other partners.

PRODUCT DEVELOPMENT

Today, Allenex SSP products have a strong market position in field of technology. Products are updated on an ongoing basis and the strategy is to offer solutions that are as complete as possible. In line with this, continuous product development is carried out to enable the company to maintain its market leading position in SSP technology. Allenex continues to develop the existing product line to secure high performance SSP typing.

The company is also reviewing solutions adapted for laboratories looking for SSP technology to attain a higher degree of automation, used as a complement to the SSO- and SBT techniques. In 2012, Allenex started the roll out of Olerup SSP® Add-ons as a complement to automated techniques (SSO and SBT). This product line will be expanded going forward.

Allenex development work also includes adapting the company's current SSP products to SBT Resolver™, in order to meet customer needs of flexibility in HLA typing. This includes both SSP products, such as Olerup SSP® Add-ons, as well as more general SSP kits based on areas where automated techniques have proved to be insufficient.

At the initiative of leading transplantation centers, several national and regional clinical trials using the cross-match test XM-ONE®, focused on antibody detection, commenced

in 2012-2013, both in the U.S. and Europe. These ongoing trials are aimed at further demonstrating the product's clinical value. Interest is also being shown by countries in Asia, with studies either ongoing or being planned in South Korea, Taiwan, India and China

SIGNIFICANT EVENTS IN THE GROUP

Significant events in the first quarter

- The Allenex subsidiary AbSorber, in collaboration with EUROSTAM, a consortium of European transplantation centers, received a grant under the EU Commissions 7th Framework Programme, FP7. The purpose is to improve the results of kidney transplants among patients with higher risks of complications due to significant genetic deviation from the donor. The Allenex cross-test XM-ONE® will be used throughout the project. Of the total EU grant of EUR 2.6 million, AbSorber will receive EUR 215,000 over a three-year period.
- A leading U.S. based HLA laboratory chose Allenex U.S. distribution company, Olerup Inc. as supplier of sequence-based HLA typing (SBT). The laboratory, which is one of the ten largest tissue typing laboratories in the U.S., has been evaluating and validating SBT Resolver™ from Allenex partner Conexio Genomics for some time. The laboratory has already placed its initial order, which also includes software Assign-SBT™ 3.6+. The yearly sales value of the contract is estimated at more than SEK 2 million.

Significant events in the second quarter

- Allenex entered into an agreement regarding the refinancing of its existing loans. Allenex and the other companies in the group had a bank loan of SEK 30 million as well as a SEK 31 million convertible loan that matured on June 30, 2013. The refinancing process involved repaying the above mentioned loans as well as an additional bank loan of SEK 27 million, while securing a new bank loan of SEK 90. The new loan is being provided by Allenex primary bank Danske Bank, at an amount of SEK 70 million, and by the company's principal owners FastPartner AB (publ) and Mohammed Al Amoudi, at an amount of SEK 20 million. The loan (SEK 90 million) has a term of three years and a current interest rate of 5.8%. (The average interest today is 5.6%)
- ONColog Medical filed for bankruptcy in May. Allenex owns 14.9% of ONColog. The company's bankruptcy will not have any impact on Allenex results, as the company's shares in ONColog were previously written down to zero.
- Allenex sold its holdings in AnaMar in June to the company's principal owner Koncentra Holding for a consideration of SEK 1.7 million. Allenex holdings corresponded to around 2.1 percent of AnaMar's total share

capital. From an accounting perspective, the holdings are reported as zero, meaning that the transfer entails a corresponding gain during the second quarter 2013.

- Allenex Olerup SSP products for HLA typing were approved for sale in Mexico. The application was handled by Olerup's local representative Biodist S.A. de C.V., which is a leading player in the Mexican HLA market. Sales started immediately, with the Mexican sales team already up to speed on the new range of products.
- Michael Petruny, General Manager of Olerup Inc. resigned after heading the company for three years.

Significant events in the third quarter

- Allenex application to sell AbSorber's antibody detection product, XM-ONE®, in Mexico has been approved by the local regulatory bodies. AbSorber developed and manufactures XM-ONE® for the detection of HLA and non-HLA antibodies between donors and recipients prior to organ transplantation. The application was handled by Allenex partner Biodist S.A. de C.V.
- On October 7, Gordon Hill was appointed National Sales Director, responsible for sales and operations of Olerup Inc., Allenex sales company in the US. He joins the company from the current U.S. market leader One Lambda/Thermo Fisher, where he was head of Technical Sales. Mr. Hill brings with him an extensive network of contacts at transplant laboratories on the North American market.

Significant events in the fourth quarter

- Allenex has no significant events to report in the fourth quarter

Significant events after the period end

- Allenex has no significant events to report after the period end.

FINANCIAL POSITION, CASH FLOW AND FINANCING

Consolidated operating income for the year amounted to SEK 9.6 million (7.9). The results include realized and unrealized currency effects corresponding to a loss of SEK 1.9 million (-3.7).

The group's operations are financed by shareholders' equity and loans. Interest-bearing liabilities amounted to SEK 98.5 million (99.0), primarily secured to finance the acquisition of Olerup SSP and AbSorber.

The consolidated equity/assets ratio was 63 percent (63). Consolidated equity was SEK 215.8 million (216.2), corresponding to SEK 1.79 per share (1.80). Cash and cash equivalents amounted to SEK 10.0 million (14.3). Cash flow

from operating activities before changes in working capital for the year was SEK -1.6 million (-10.8).

Risks and uncertainties

Allenex has long been a well-established business with well-known products in the field of genomic HLA typing based on SSP technology, with a significant market share. At the same time, the company faces market risk in the form of competition from other producers, the transition to more automated typing processes as well as new technologies, which may make it difficult for the company to maintain market share and margins.

Operational risk is primarily tied to the company's ability to constantly update its product range and to produce continually updated test kits in pace with market demand.

In 2011, the addition of products sold and distributed on the basis of cooperation agreements with other companies increases opportunities to strengthen market position and profitability, while it also carries an increased risk in light of the commitments with respect to resource investments and costs resulting from such agreements. The SBT products from the Australian company Conexio Genomics in particular are expected to achieve significant sales. At the same time, this involves significant competition and market risk. Establishing the products has proven to take longer than planned and there is a risk that they may not attain the anticipated success. The ability to deliver the right quality on time has both a short and long-term significance for the business. For example, the inability of the partner to deliver due to production downtime could have a substantial negative effect on sales.

The transplantation test XM-ONE® is primarily used as a research product by larger centers. Work is underway to get the product established in broad clinical use. This has proven to take longer than planned and there is a risk that the product may not attain the success anticipated. This in turn could have a negative on the value of the company's intangible assets and other assets. To date, XM-ONE® is a unique product in its area and has significant patent protection. However, there is a risk that the company's competitors may challenge these patents or otherwise introduce competing test methods.

A large part of Allenex sales are carried out in currencies other than SEK, mostly in EUR but also a significant share in USD. A lesser portion of purchases are also made in currencies other than SEK. This may signify a currency risk for the company. Allenex does not conduct currency hedging activities.

Attracting and maintaining qualified personnel for development, production, marketing, sales, logistics and administration is essential to group performance.

The value of the company is partly dependent on its ability to maintain and protect patents, other intellectual property rights and specific expertise. Patent protection for medical, medtech and biotech products can be uncertain and involve complex legal and technical issues. Patents must usually be sought and maintained in several jurisdictions, and issued

patents may be challenged, invalidated and circumvented. For Allenex or its subsidiaries this may mean loss of or shortened patent protection, which in turn may mean that the company cannot prevent competitors from marketing similar products. The uncertainty associated with patents and patent litigation and other patent processes, may have a negative impact on the competitiveness of Allenex and its subsidiaries, which in turn may have a negative effect on their business.

Both clinical trials and the marketing and sales of products pose a significant risk in terms of product liability. When deemed necessary, the company obtains product liability insurance. No assurance can be given that insurance will cover future claims against Allenex or its subsidiaries.

Some of the companies are dependent on approval through clinical trials or decisions from public authorities. There are no guarantees that an associated company will achieve satisfactory results in such trials, or that the required regulatory approval will be granted.

The group's customer relations are stable and long-term, with historically low credit losses. Credit evaluations are carried out on new customers. Credit risk is currently assessed as low, but any change in a negative direction could impact the company's results and financial position.

Part of the financing was raised at variable interest rates, therefore rising interest rates could lead to lower returns for the company, which in turn could affect the company's results and financial position.

Based on the current circumstances, the group is of the opinion that it has sufficient liquidity to conduct its operations according to current plans. There is a risk that market conditions and sales will develop negatively, which may have a negative effect on liquidity. The group's ability to refinance maturing loans may also be adversely impacted by group performance and overall conditions in the financial markets.

The company's cash and cash equivalents are placed in liquid assets with low credit risk.

Financial instruments

Allenex financial instruments consist of trade account receivables, cash and cash equivalents, trade accounts payable, accrued supplier expenses, interest-bearing liabilities as well as participations in associated companies and other holdings. Liabilities to credit institutions have variable interest rates. Liabilities to shareholders have fixed interest rates, which essentially correspond to current market rates. Participations in associated companies and other holdings are valued at fair value via the income statement based on input corresponding to level 3 in accordance with IFRS 7. With the sale of the company's shares in AnaMar, Allenex earlier portfolio of holdings in associated companies has been completely divested. The holding was previously reported at nil, and consequently no changes in value occurred during the year. Other financial assets and liabilities have short life spans. The fair value of all financial instruments is deemed to approximate the book value. Allenex

has not netted any financial assets or liabilities and has not entered into any offset agreements.

RELATED PARTY TRANSACTIONS

Transactions with related parties are detailed in Note 11 of the 2012 Annual Report. Besides the information presented below, there is no substantial change to report in the content or scope of these transactions.

In conjunction with the refinancing that took place in the second quarter 2013, Allenex largest owners in terms of ownership stake, FastPartner AB (publ) and Mohammed Al Amoudi, provided a loan totaling SEK 20 million. The loan runs with a fixed rate of 10%. The convertible loan from SSP Primers AB was settled in conjunction with the refinancing.

PARENT COMPANY

Revenues for the year amounted to SEK 3.1 million (2.6). Operating loss in 2013 was SEK 13.6 million (-13.7). The company's long-term intragroup receivables amounted to SEK 93.1 million (99.9). Cash and cash equivalents was SEK 2.1 million (5.5). Cash flow from operating activities before changes in working capital was a negative SEK 14.5 million (-17.9). The parent company had 4 employees (4) at the year-end.

SHARE AND SHAREHOLDERS

Principal shareholders, 12/31/2013	Number of shares	Ownership stake %
Mohammed Al Amoudi	43,678,850	36.3
FastPartner AB (publ)	38,886,307	32.3
Xenella Holding AB *)	11,174,755	9.3
Mannersons Fastighets AB	6,774,152	5.6
Avanza Pension	2,250,718	1.9
Clearstream Banking S.A	545,650	0.5
Handelsbanken fonder	495,669	0.4
Others	16,482,347	13.7
Total	120,288,448	100.0

*) Xenella Holding AB is jointly owned by Mohammed Al Amoudi and FastPartner AB (publ).

Accounting principles

Allenex applies International Financial Reporting Standards (IFRS) as adopted by the EU and the Swedish Annual Accounts Act. This year-end report was prepared in accordance with IAS 34 and the Annual Accounts Act for the group and in accordance with the Annual Accounts Act for the parent company. The accounting principles and methods of calculation applied for the group and the parent company are consistent with those used in the preparation of the most recent Annual Report.

Future report dates

Interim report, January-March: April 29, 2014

The 2013 Annual Report will be published on the company's website no later than week 17, 2014.

Interim report, January-June: August 2014

Interim report, January-September: November 2014

The Annual General Meeting will be held in Stockholm on May 13, 2014. Shareholders wishing to have matters addressed at the meeting should submit their proposals in writing to the company at the following address: Allenex AB (publ), Attn AGM 2014, Box 122 83, 102 27 Stockholm or via email to arsstamma@allenex.se. All proposals must be received by Allenex by April 4 2014 at the latest, or in sufficient time in order to guarantee that their proposals, if so required, may be included in the AGM notice.

The Board of Directors proposes that no dividend be paid for the 2013 financial year.

Stockholm, February 20, 2014

Anders Karlsson
CEO

The information in this year-end report is such that Allenex AB (publ) is required to disclose under the Securities Market Act and/or the Financial Instruments Trading Act. This report and earlier financial reports are available at www.allenex.com

This year-end report has not been subject to review by the company's auditors.

This information was released for publication on February 20, 2014 at 2pm

Consolidated statement of comprehensive income	2013	2012	2013	2012
Amounts in SEK thousand	OCT-DEC	OCT-DEC	JAN-DEC	JAN-DEC
Net sales	29,447	27,364	111,811	112,688
Changes in inventory of finished goods	-1,205	-564	3,163	220
Other revenue	922	862	3,792	3,445
	29,164	27,662	118,766	116,353
Raw materials and consumables	-4,405	-5,795	-18,870	-18,089
Other expenses	-10,210	-11,500	-43,740	-44,770
Cost of employee remuneration	-11,790	-9,244	-44,414	-43,299
Depreciation/amortization	-542	-548	-2,151	-2,262
<i>Operating income</i>	2,217	575	9,591	7,933
Results from associated companies		-	1,705	1,050
Other financial expenses and income	-1,356	-904	-5,755	-6,548
<i>Results after financial items</i>	861	-329	5,541	2,435
Taxes	-707	1,179	-3,237	-2,160
<i>Net income/loss for the year</i>	155	850	2,304	275
Other comprehensive results for the period				
<i>Components that will not be reclassified to net income</i>	-		-	
<i>Components that will be reclassified to net income</i>				
Translation differences	155	525	766	779
<i>Comprehensive income for the period</i>	309	1,375	3,070	1,054
Results for the period pertaining to:				
Owners of the parent company	2,322	3,983	5,603	4,452
Non-controlling interests	-2,167	-3,133	-3,299	-4,177
Comprehensive results for the year pertaining to:				
Owners of the parent company	2,479	4,303	6,081	4,655
Non-controlling interests	-2,169	-2,928	-3,011	-3,601
Earnings per share, basic and diluted, SEK	0.02	0.03	0.05	0.04
Average number of outstanding shares, basic and diluted	120,288,448	120,288,448	120,288,448	120,288,448
Number of shares at the period end	120,288,448	120,288,448	120,288,448	120,288,448

Consolidated statement of financial position

	2013	2012
Amounts in SEK thousand	DEC 31	DEC 31
Assets		
Goodwill	214,806	214,541
Other intangible assets	63,248	64,220
Tangible assets	3,781	4,496
Participations in associated companies and other holdings	0	0
Deferred tax assets	7,077	8,711
<i>Total non-current assets</i>	<i>288,912</i>	<i>291,968</i>
Inventories	29,733	21,701
Current receivables	15,492	14,912
Cash and cash equivalents	10,046	14,327
<i>Total current assets</i>	<i>55,271</i>	<i>50,940</i>
Total assets	344,183	342,908
Equity and liabilities		
Equity	215,859	216,196
Interest-bearing non-current liabilities	82,874	18,000
Non-interest bearing non-current liabilities and provisions	13,446	13,172
Interest-bearing current liabilities	14,926	80,774
Non-interest bearing current liabilities and provisions	17,078	14,766
Total equity and liabilities	344,183	342,908

Consolidated statement of changes in equity

	2013	2012
Amounts in SEK thousand	DEC 31	DEC 31
Opening balance	216,196	219,810
Dividends paid to non-controlling interests	-3,407	-4,668
Comprehensive results for the year	3,070	1,054
<i>Closing balance</i>	<i>215,859</i>	<i>216,196</i>
Of which pertaining to:		
Owners of the parent company	224,699	222,025
Non-controlling interests	-8,840	-5,829

Consolidated statement of cash flows

	2013	2012
Amounts in SEK thousand	JAN-DEC	JAN-DEC
Operating income	9,591	7,933
Adjustment for items not included in the cash flow	2,678	3,794
Financial items	-4,465	-7,353
Taxes paid	-1,328	-3,770
<i>Cash flow from operations before changes in working capital</i>	<i>6,476</i>	<i>604</i>
Increase (-)/Decrease(+) in inventories	-7,825	-890
Increase (-)/Decrease(+) in operating receivables	-2,147	-3,475
<i>Increase (-)/Decrease(+) in operating liabilities</i>	<i>1,905</i>	<i>-7,025</i>
<i>Cash flow from operating activities</i>	<i>-1,591</i>	<i>-10,786</i>
Cash flow from investing activities	1,237	961
Cash flow from financing activities	-3,874	-56,403
Cash flow for the year	-4,228	-66,228
Cash and cash equivalents at the start of the year	14,327	80,530
<i>Exchange rate differences in liquid assets</i>	<i>-53</i>	<i>25</i>
<i>Cash and cash equivalents at the year-end</i>	<i>10,046</i>	<i>14,327</i>

Parent company income statement

	2013	2012	2013	2012
Amounts in SEK thousand	OCT-DEC	OCT-DEC	JAN-DEC	JAN-DEC
Other revenue	925	650	3,142	2,552
Other external expenses	-2,108	-2,065	-9,211	-8,477
Personnel costs	-1,949	-1,353	-7,421	-7,625
Depreciation/amortization	-31	-43	-141	-174
<i>Operating results</i>	-3,163	-2,811	-13,631	-13,724
Write down of shares in the parent company	-	-2,000	-	-2,000
Results from associated companies	-	0	1,705	1,050
Other financial expenses and revenues	-435	-187	-822	237
<i>Results after financial items</i>	-3,598	-4,998	-12,748	-14,437
<i>Allocations</i>				
Group contributions received	32,628	31,648	32,628	31,648
Group contributions paid	-25,721	-16,618	-25,721	-16,618
<i>Results before tax</i>	3,309	10,032	-5,841	593
Taxes	0	-297	0	-297
<i>Results for the period</i>	3,309	9,735	-5,841	296

Parent company statement of comprehensive income

Results for the period	3,309	9,735	-5,841	296
<i>Other comprehensive results for the period</i>	-	-	-	-
<i>Comprehensive results for the period</i>	3,309	9,735	-5,841	296

Parent company balance sheet

	2013	2012
Amounts in SEK thousand	DEC 31	DEC 31
Assets		
Intangible and tangible assets	217	322
Shares in subsidiaries	57,378	57,378
Participations in associated companies	0	0
Non-current intra-group receivables	93,102	99,872
Deferred tax assets	1,626	1,626
<i>Total non-current assets</i>	152,323	159,198
Current receivables	54,505	38,128
Cash and bank	2,118	5,480
<i>Total current assets</i>	56,623	43,608
Total assets	208,946	202,806
Equity and liabilities		
Equity	157,780	163,621
Non-current liabilities	19,349	0
Current liabilities	31,817	39,185
Total equity and liabilities	208,946	202,806
Changes in equity, parent company		
Opening balance	163,621	163,325
Net income/loss for the year	-5,841	296
Closing balance	157,780	163,621

Parent company statement of cash flows

	2013	2012
	JAN-DEC	JAN-DEC
Amounts in SEK thousand		
Operating income	-13,631	-13,724
Adjustments for items not included in the cash flow	141	174
Financial items	-999	-4,320
Taxes paid	0	0
<i>Cash flow from operating activities before changes in working capital</i>	<i>-14,489</i>	<i>-17,870</i>
Increase (-)/Decrease(+) in operating receivables	-111	441
Increase (-)/Decrease(+) in operating liabilities	-251	-3,909
<i>Cash flow from operating activities</i>	<i>-14,851</i>	<i>-21,338</i>
Cash flow from investing activities	22,489	12,274
Cash flow from financing activities ¹⁾	-11,000	-40,776
Cash flow for the year	-3,362	-49,840
Cash and cash equivalents at the start of the year	5,480	55,320
<i>Cash and cash equivalents at the year-end</i>	<i>2,118</i>	<i>5,480</i>

1) Amortization of convertible loan of SEK 31 million, newly raised shareholder loan of SEK 20 million in 2013

Key figures

	2013	2012
	JAN-DEC	JAN-DEC
Net sales, SEK thousand	111,811	112,688
Operating income, SEK thousand	9,591	7,933
Net income, SEK thousand	2,304	275
Earnings per share, basic and diluted, SEK	0.05	0.04
Equity per share, SEK	1.79	1.80
Equity/assets ratio, %	63	63
Return on equity, %	2	2
Average number of employees	55	54
Number of shares outstanding at the year-end	120,288,448	120,288,448
Average number of shares outstanding	120,288,448	120,288,448
Share price at the year-end, SEK	2.42	0.85
Market cap, SEK thousand	291,098	102,245

Definitions:

Earnings per share	Earnings after tax attributable to the parent company divided by the average number of outstanding shares.
Equity per share	Equity divided by the number of outstanding shares at the period end.
Equity/assets ratio	Equity at the year-end in relation to total assets.
Return on equity	Results attributable to parent company shareholders divided by equity attributable to the owners of the parent.

Companies in the Allenex group

MANUFACTURING AND R&D COMPANIES



Olerup SSP AB is world leading in the development of kits for genomic HLA typing, based on SSP technology. The product is used prior to a transplantation to match the donor and recipient. The better the match the lower the risk of complications following transplantation. HLA typing is a standard procedure prior to bone marrow transplantation (hematopoietic stem cell transplantation) and is also used in conjunction with organ transplants (kidney, lung, heart, etc.). In 2011, Olerup SSP entered into a five-year exclusive global agreement (excl. Australia, New Zealand and Taiwan) with Conexio Genomics, Perth, Australia. Allenex ownership stake in Olerup SSP AB is 91 percent. For more information visit www.olerup-ssp.com



AbSorber develops products that facilitate successful transplantation. AbSorber's transplantation test XM-ONE®, identifies antibodies that play a key role in causing rejection subsequent to transplantation. The company's research portfolio also includes a patented ABO column for transplantations between people of different blood groups and an ABO diagnostic test that measures the occurrence of blood group antibodies. Allenex ownership stake of AbSorber is 98 percent. For more information visit www.absorber.se

SALES AND DISTRIBUTION COMPANIES



Olerup GmbH, based in Vienna, is responsible for sales, distribution and logistics in Europe and the rest of the world excluding North, Central and South America as well as the Nordic region. Sales encompass Olerup SSP's HLA typing products and AbSorber's XM-ONE® transplantation test. Furthermore, from mid-year 2011, the company also sells and distributes products from the Australian company Conexio Genomics. Sales are conducted by a proprietary sales team in Germany, Austria, Belgium, the Netherlands and Slovenia, as well as the Nordic region. Sales in other markets are handled by sub-distributors. The company is owned by Olerup International, in which Allenex has an ownership stake of 75 percent. For more information visit www.olerup.com



Olerup Inc., domiciled in West Chester, PA, USA, is responsible for the sales, distribution and logistics of Olerup SSP and AbSorber products in the North American market. Furthermore, since mid-2011, the company sells and distributes products from the Australian company Conexio Genomics. The company has its own sales organization in the US, while sales in Canada and Central and South America are handled by sub distributors. AbSorber owns 50 percent of the company. For more information visit www.olerup.com